Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors

Acta Oncologica

Volumn 52, Issue 2, 2013, Pages 447-454

  Husson, Olga ^a,b   Haak, Harm R ^c   Mols, Floortje ^a,b   Nieuwenhuijzen, Grard A ^d   Nieuwlaat, Willy Anne ^e   Reemst, Peter H ^c   Huysmans, Dyde A ^d   Toorians, Arno W ^f   Van De Poll Franse, Lonneke V ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e Elisabeth Hospital Tilburg   (Netherlands)

^f ST ANNA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CANCER PATIENT; CANCER SURVIVOR; CONFERENCE PAPER; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; THYROID CANCER; THYROID CANCER SPECIFICHEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT TOOL; DIFFERENTIATED THYROID CANCER; MULTIMODALITY CANCER THERAPY; QUALITY OF LIFE INDEX; THYROID CANCER HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVORS; THYROID NEOPLASMS; YOUNG ADULT;

RADIOACTIVE IODINE; UNCLASSIFIED DRUG;

EID: 84872521439     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.718445     Document Type: Conference Paper

References (21)

1. Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P. Descriptive epidemiology of thyroid cancer in France: Incidence, mortality and survival. Ann Endocrinol (Paris) 2010; 71: 95-101.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2010.
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-7.
4. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4): 143-6.
5. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE. Quality of life with well-differentiated thyroid cancer: Treatment toxicities and their reduction. Thyroid 2004; 14: 133-40.
6. Tagay S, Herpertz S, Langkafel M, Erim Y, Bockisch A, Senf W, et al. Health-related quality of life, depression and anxiety in thyroid cancer patients. Qual Life Res 2006; 15: 695-703.
7. Holzner B, Kemmler G, Kopp M, Moschen R, Schweigkofl er H, Dunser M, et al. Quality of life in breast cancer patients-not enough attention for long-term survivors? Psychosomatics 2001; 42: 117-23.
8. National Coalition for Cancer Survivorship. [cited 2012 Jun 4]. Available from: http://www.canceradvocacy.org/
9. Husson O, Haak HR, Oranje WA, Mols F, Reemst PH, van de Poll-Franse LV. Health-related quality of life among thyroid cancer survivors: Asystematic review. Clin Endocrinol (Oxf) 2011; 75: 544-54.
10. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-9.
11. Dagan T, Bedrin L, Horowitz Z, Chaushu G, Wolf M, Kronenberg J, et al. Quality of life of well-differentiated thyroid carcinoma patients. JLaryngol Otol 2004; 118: 537-42.
12. Shah MD, Witterick IJ, Eski SJ, Pinto R, Freeman JL. Quality of life in patients undergoing thyroid surgery. JOtolaryngol 2006; 35: 209-15.
13. Gning I, Trask PC, Mendoza TR, Harle MT, Gutierrez KA, Kitaka SA, et al. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology 2009; 76: 59-68.
14. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: Aquality-of-life instrument for use in international clinical trials in oncology. JNatl Cancer Inst 1993; 85: 365-76.
15. Blazeby J, Sprangers MA, Cull A, Groenvold M, Bottomley A. EORTC quality of life group: Guidelines for developing questionnaire modules, Brussels: EORTC; 2002.
16. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: Guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life. Qual Life Res 1993; 2: 287-95.
17. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to developing questionnaire modules: An update and overview. EORTC Quality of Life Study Group. Qual Life Res 1998; 7: 291-300.
18. Bottomley A, Vachalec S, Bjordal K, Blazeby J, Flechtner H, Ruyskart P. The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. Eur J Cancer 2002; 38: 1611-4.
19. Velikova G, Weis J, Hjermstad MJ, Kopp M, Morris P, Watson M, et al. The EORTC QLQ-HDC29: Asupplementary module assessing the quality of life during and after high-dose chemotherapy and stem cell transplantation. Eur J Cancer 2007; 43: 87-94.
20. Nunnally J C, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
21. Kaiser HF. An index of factorial simplicity. Psychometrika 1974; 39: 31-6.